S&P 500

6.114,63

-0,01%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

0EE0

Uniqure Nv (0EE0)

Uniqure Nv

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:LSE:0EE0

1

Data	Hora	Fonte	Título	Código	Companhia
03/02/2025	09:05	UK Regulatory	uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease	LSE:0EE0	Uniqure Nv
30/01/2025	09:37	UK Regulatory	uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS	LSE:0EE0	Uniqure Nv
08/01/2025	09:05	UK Regulatory	uniQure Announces Pricing of its Public Offering	LSE:0EE0	Uniqure Nv
07/01/2025	18:49	UK Regulatory	uniQure Announces Proposed Public Offering	LSE:0EE0	Uniqure Nv
10/12/2024	09:05	UK Regulatory	uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease	LSE:0EE0	Uniqure Nv
21/11/2024	09:05	UK Regulatory	uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy	LSE:0EE0	Uniqure Nv
05/11/2024	09:05	UK Regulatory	uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress	LSE:0EE0	Uniqure Nv
15/10/2024	08:05	UK Regulatory	uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS	LSE:0EE0	Uniqure Nv
23/09/2024	08:05	UK Regulatory	uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease	LSE:0EE0	Uniqure Nv
15/08/2024	08:05	UK Regulatory	uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease	LSE:0EE0	Uniqure Nv
01/08/2024	08:05	UK Regulatory	uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update	LSE:0EE0	Uniqure Nv
23/07/2024	08:05	UK Regulatory	uniQure Announces Closing of Sale of Manufacturing Facility to Genezen	LSE:0EE0	Uniqure Nv
09/07/2024	08:05	UK Regulatory	uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease	LSE:0EE0	Uniqure Nv
01/07/2024	08:05	UK Regulatory	uniQure Announces Sale of Commercial Manufacturing Facility to Genezen	LSE:0EE0	Uniqure Nv
03/06/2024	08:05	UK Regulatory	uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease	LSE:0EE0	Uniqure Nv
07/05/2024	08:05	UK Regulatory	uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress	LSE:0EE0	Uniqure Nv
28/02/2024	09:05	UK Regulatory	uniQure Announces 2023 Financial Results and Highlights Recent Company Progress	LSE:0EE0	Uniqure Nv